The specter of generic rivalry has consistently loomed over copyright’s famous drug, Sildenafil, triggering questions about the outlook of connected medicinal stakes. While first periods saw substantial returns, the patent expiration has allowed the door for discounted copies, likely diminishing profitability and presenting a genuine risk for sta